Trial · NCT02357810
Adverse events310
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 310
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 112 | 151 | |
| other | Blood and lymphatic system disorders - Other, specify | Blood and lymphatic system disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 5 | 151 | |
| other | Disseminated intravascular coagulation | Blood and lymphatic system disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 2 | 151 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 6 | 151 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 1 | 151 | |
| other | Aortic valve disease | Cardiac disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 1 | 151 | |
| other | Atrial fibrillation | Cardiac disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 1 | 151 | |
| other | Atrioventricular block first degree | Cardiac disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 1 | 151 | |
| other | Cardiac disorders - Other, specify | Cardiac disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 1 | 151 | |
| other | Chest pain - cardiac | Cardiac disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 6 | 151 | |
| other | Heart failure | Cardiac disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 2 | 151 | |
| other | Left ventricular systolic dysfunction | Cardiac disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 2 | 151 | |
| other | Palpitations | Cardiac disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 1 | 151 | |
| other | Pericardial effusion | Cardiac disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 1 | 151 | |
| other | Sinus bradycardia | Cardiac disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 16 | 151 | |
| other | Sinus tachycardia | Cardiac disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 20 | 151 | |
| other | Disease progression | Ear and labyrinth disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 4 | 151 | |
| other | Ear pain | Ear and labyrinth disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 5 | 151 | |
| other | Hearing impaired | Ear and labyrinth disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 1 | 151 | |
| other | Middle ear inflammation | Ear and labyrinth disorders | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 1 | 151 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02357810/events